263 related articles for article (PubMed ID: 20006922)
61. Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney.
Li J; Li XL; Li CQ
Am J Med Sci; 2023 Dec; 366(6):404-412. PubMed ID: 37699444
[TBL] [Abstract][Full Text] [Related]
62. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study).
Nakamura M; Funakoshi T; Kataoka S; Horimatsu T; Nishikawa Y; Matsubara T; Mizukami T; Goto T; Tsuchihashi K; Baba E; Tsumura T; Mihara Y; Hamaguchi T; Yanagita M; Muto M
BMC Cancer; 2022 May; 22(1):515. PubMed ID: 35525917
[TBL] [Abstract][Full Text] [Related]
63. VEGF inhibition and renal thrombotic microangiopathy.
Katavetin P; Katavetin P
N Engl J Med; 2008 Jul; 359(2):205-6; author reply 206-7. PubMed ID: 18614790
[No Abstract] [Full Text] [Related]
64. [Effect of Proteinuria in Patients Receiving Anti-VEGF Therapy for Advanced Colorectal Cancer].
Kinugasa S; Horikawa M; Kawashima T; Monma H; Hori H; Kobayashi I; Takase S
Gan To Kagaku Ryoho; 2019 Aug; 46(8):1334-1336. PubMed ID: 31501383
[TBL] [Abstract][Full Text] [Related]
65. Progressive bevacizumab-associated renal thrombotic microangiopathy.
Uy AL; Simper NB; Champeaux AL; Perkins RM
NDT Plus; 2009 Feb; 2(1):36-9. PubMed ID: 25949282
[TBL] [Abstract][Full Text] [Related]
66. Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?
El Rassy E; El Karak F; Rizkallah J; Chelala D
Iran J Kidney Dis; 2016 Jul; 10(4):169-75. PubMed ID: 27514761
[TBL] [Abstract][Full Text] [Related]
67. Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?
Izzedine H; Sène D; Hadoux J; Gharbi C; Bourry E; Massard C; Soria JC
Ann Oncol; 2011 Feb; 22(2):487-90. PubMed ID: 21278225
[No Abstract] [Full Text] [Related]
68. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract][Full Text] [Related]
69. [Management of side effects of targeted therapies in renal cancer: nephrological side effects].
Izzedine H; Négrier S; Neuzillet Y; Zini L
Bull Cancer; 2011; 98(3 Suppl):S7-S18. PubMed ID: 25819129
[TBL] [Abstract][Full Text] [Related]
70. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.
Saloustros E; Androulakis N; Vamvakas L; Mavroudis D; Georgoulias V
Case Rep Oncol; 2010 Oct; 3(3):368-71. PubMed ID: 21537380
[TBL] [Abstract][Full Text] [Related]
71. Anti-VEGF Cancer Therapy in Nephrology Practice.
Izzedine H
Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627
[TBL] [Abstract][Full Text] [Related]
72. [Drug-induced proteinuria].
Ogawa M
Nihon Jinzo Gakkai Shi; 2012; 54(7):981-4. PubMed ID: 23234208
[No Abstract] [Full Text] [Related]
73. Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review.
Kato T; Kurasawa S; Takezawa K; Fujiwara Y; Yasuda Y; Ando Y
Anticancer Res; 2024 Mar; 44(3):889-894. PubMed ID: 38423640
[TBL] [Abstract][Full Text] [Related]
74. An unusual kidney presentation of severe proteinuria in a 2-year-old girl: Answers.
Nawata A; Morishita T; Hisano S; Nakagawa K; Kusuhara K; Nakayama T
Pediatr Nephrol; 2021 May; 36(5):1153-1157. PubMed ID: 32789578
[No Abstract] [Full Text] [Related]
75. Studies on proteinuria with special reference to immunochemically determined differential protein clearances.
SOOTHILL JF
Guys Hosp Rep; 1962; 111():355-69. PubMed ID: 13978247
[No Abstract] [Full Text] [Related]
76. Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer.
Hanna PE; Anumolu RK; Motwani SS; Chen KL; Katz-Agranov N; Green-Lingren O; Yilmam OA; Jhaveri KD; Kitchlu A; Kala J; Sise ME; Gupta S
Kidney Int Rep; 2024 Jun; 9(6):1897-1902. PubMed ID: 38899179
[No Abstract] [Full Text] [Related]
77. [Management of proteinuria].
Arrestier R; Lang P; Audard V
Rev Prat; 2016 Feb; 66(2):e60. PubMed ID: 30512347
[No Abstract] [Full Text] [Related]
78. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Tesařová P; Tesař V
Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
[TBL] [Abstract][Full Text] [Related]
79. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
80. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
Estrada CC; Maldonado A; Mallipattu SK
J Am Soc Nephrol; 2019 Feb; 30(2):187-200. PubMed ID: 30642877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
